Hereditary angioedema: attack treatment & prophylaxis
For confirmed or strongly-suspected HAE (C1-INH deficiency, type I/II, or HAE with normal C1-INH): routes an acute attack to early on-demand therapy, and names the agents that do NOT work and why, separates short-term (procedural) prophylaxis, and walks first- versus second-line long-term prophylaxis. Bakes in the bradykinin-vs-histamine teaching, the fresh-frozen-plasma caveat, and the pregnancy/lactation/child rules.
Evidence tier: Guideline-derived.
Decision points
- What do you need to manage now?
- Airway (laryngeal / tongue / throat) involvement?
- Start long-term prophylaxis?
Do-not-miss pitfalls
- Antihistamines, corticosteroids, and epinephrine do NOT reverse HAE attacks, their failure is a diagnostic clue, not a reason to redose, and must never delay targeted on-demand therapy.
- Laryngeal, tongue, or throat swelling carries substantial mortality, treat immediately and seek emergency care even after self-treatment, with a low threshold for early elective intubation.
- Fresh frozen plasma can precipitously WORSEN an attack: it supplies bradykinin-generating substrate (HMW kininogen, prekallikrein, factor XII) as well as C1-INH. Use only when no approved on-demand agent is available, prefer solvent-detergent–treated plasma, and protect the airway.
- Every patient, even on long-term prophylaxis, must keep ≥2 doses of on-demand medication and a written action plan; prophylaxis reduces but does not eliminate attacks.
- Do not require patients to fail anabolic androgens before offering first-line long-term prophylaxis; androgens are second-line with a heavy side-effect burden.
- In pregnancy, lactation, and children, plasma-derived C1-INH is the preferred agent across on-demand, short-term, and long-term prophylaxis; anabolic androgens are contraindicated in pregnancy/lactation and avoided in children, and tranexamic acid is excreted in breast milk.
- Estrogen-containing contraceptives or HRT and ACE inhibitors can trigger or worsen HAE, avoid them.
- Ecallantide must be administered by a healthcare professional (anaphylaxis risk, black-box warning); the other on-demand agents are self-administered.
Evidence & citations
- Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132-150. doi:10.1016/j.jaip.2020.08.046
- Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema, The 2021 revision and update. Allergy. 2022;77(7):1961-1990. PMID 35006617
- EKTERLY (sebetralstat) US prescribing information. KalVista Pharmaceuticals; 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219301s000lbl.pdf
- ORLADEYO (berotralstat) US prescribing information. BioCryst Pharmaceuticals; 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214094s003lbl.pdf
- ANDEMBRY (garadacimab-gxii) US prescribing information. CSL Behring; 2025. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=07b0b671-db81-49f0-a402-0c0219db7fa2
- DAWNZERA (donidalorsen) US prescribing information. Ionis Pharmaceuticals; 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219407s000lbl.pdf
Clinician decision support. Verify against the cited source. Not a substitute for clinical judgment. 100% on-device; no patient data is stored or transmitted.